Alto Neuroscience (ANRO) Other Operating Expenses (2023)

Alto Neuroscience (ANRO) reported Other Operating Expenses of $30.1 million for Q4 2023.

Alto Neuroscience (ANRO) Other Operating Expenses (2023) Analysis & Trends

Alto Neuroscience (ANRO) has 1 years of Other Operating Expenses data on file, last reported at $30.1 million in Q4 2023.

For the quarter ending Q4 2023, Other Operating Expenses changed N/A year-over-year to $30.1 million; the trailing twelve-month figure through Sep 2024 stood at $30.1 million (changed N/A YoY), and the FY2023 full-year result was $30.1 million, changed N/A from the prior year.
Other Operating Expenses was little changed at $30.1 million in Q4 2023.
In the past five years, Other Operating Expenses ranged from a high of $30.1 million in Q4 2023 to a low of $30.1 million in Q4 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn
7	Belite Bio	61.40 Bn	61.40 Bn	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn
9	Revolution Medicines	37.37 Bn	37.37 Bn	-
10	Alto Neuroscience	869.36 Mn	869.36 Mn	-

Download Data

Date	Value
Dec 31, 2023	30.09 Mn